Breast Cancer Archives | VJOncology

The Breast Cancer Channel on VJOncology is supported by Gilead. These supporters have no influence over the production of the content.

View overview page

Emerging toxicities associated with ADCs

Sung-Bae Kim • 11 May 2023

ADCs: is chemotherapy dead?

Eva Ciruelos • 16 Mar 2023

Optimizing treatment in patients with early-stage HER2-positive breast cancer

Hope S. Rugo • 17 Mar 2023

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

Ian Krop • 7 Dec 2022

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer

Saranya Chumsri • 8 Dec 2022

neoHIP: neoadjuvant HER2-targeted therapy +/- IO with pembrolizumab

Heather McArthur • 7 Dec 2022

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

Ian Krop • 8 Dec 2022

HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC

Erika Hamilton • 15 Dec 2022

Remaining questions surrounding HER2-low breast cancer – how low can you go?

Paolo Tarantino • 8 Dec 2022

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

Erika Hamilton • 15 Dec 2022

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Erika Hamilton • 15 Dec 2022

DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

Erika Hamilton • 15 Dec 2022

Anti-HER2 CAR macrophages for solid tumors

Yara Abdou • 13 Dec 2022

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

Paolo Tarantino • 8 Dec 2022

Immunotherapy in breast cancer

Jon Amund Kyte • 8 Dec 2022

The predictive value of treatment response after neoadjuvant therapy

Virginia Kaklamani • 7 Dec 2022

1
2
3
4
5
…
8
Next